

February 3, 2021

To,  
**Dy. General Manager**  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001.

To,  
**The Manager – Listing,**  
The National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051.

**Ref: Scrip Code: 532296**

**Ref: Scrip Name: GLENMARK**

Dear Sir,

**Sub: Glenmark Pharmaceuticals receives ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg**

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber**  
**Company Secretary & Compliance Officer**

**Encl: as above**

Press Release

For Immediate Release

**Glenmark Pharmaceuticals receives ANDA approval for  
Topiramate Extended-Release Capsules,  
25 mg, 50 mg, 100 mg, 150 mg, and 200 mg**

**Mumbai, India; February 03, 2021:** Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, the generic version of Qudexy<sup>®1</sup> XR Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, of Upsher-Smith Laboratories, LLC.

According to IQVIA<sup>™</sup> sales data for the 12 month period ending December 2020, the Qudexy<sup>®</sup> XR Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg market<sup>2</sup> achieved annual sales of approximately \$120.8 million\*.

Glenmark's current portfolio consists of 169 products authorized for distribution in the U.S. marketplace and 43 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

**About Glenmark Pharmaceuticals Ltd**

Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark's key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). The company has been listed in the Dow Jones Sustainability Index (DJSI), under the category of emerging markets for the third consecutive year in a row. DJSI is one of the world's most respected and widely accepted sustainability benchmarks globally with only the top ranked companies in terms of Corporate Sustainability within each industry are featured in the index.

For more information, visit [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

**For more information:**

**Glenmark Media Contacts**

Udaykumar Murthy  
Senior Manager, Corporate Communications  
+91 9960377617  
[corpcomm@glenmarkpharma.com](mailto:corpcomm@glenmarkpharma.com)

<sup>1</sup>All brand names and trademarks are the property of their respective owners.

<sup>2</sup>Market includes brand and all available therapeutic equivalents

\*IQVIA™ National Sales Perspectives: Retail & Non-Retail, December 2020